# Sezary Syndrome: A Case Report and Review of Current Therapeutics

## TL;DR

This paper discusses a case of Sezary Syndrome, a rare skin cancer, and highlights the importance of early diagnosis and treatment.

## Contribution

The paper presents a new case report and emphasizes the need for early referral to dermatology for suspected Sezary Syndrome.

## Key findings

- A patient with Sezary Syndrome showed a good response to systemic therapy with bexarotene.
- Persistent rashes unresponsive to treatment may indicate Sezary Syndrome and require dermatological evaluation.

## Abstract

Sezary syndrome (SS) is a rare but aggressive type of cutaneous T-cell lymphoma (CTCL). Patients with SS have characteristic skin lesions (erythroderma) and a leukemic phase. The rash associated with CTCLs can often mimic common benign skin conditions such as psoriasis, atopic dermatitis, etc. and therefore can go undiagnosed until later stages. We present a case of a patient with SS who managed eczema for over one year with topical steroids before receiving a skin biopsy. Workup confirmed leukemic involvement, and the patient was started on systemic therapy with bexarotene. The patient continues to have a good response to systemic therapy. When treating patients with persistent rash of uncertain etiology and/or unresponsive to treatment, primary care physicians and internists need to consider SS/Mycosis fungoides as a possible differential and should have a low threshold to initiate early referral to dermatology for definitive diagnosis.